Anthem Blue Cross Blue Shield of Colorado prior authorization, page 41

CPT code lookup

Each row is one code from the public prior authorization list. The description is the procedure or service name on that source row. This is not a coverage decision.

Prior authorization codes

Prior authorization codes
CodeDescriptionSource
81233BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)Colorado Prior Authorization List, Pg 97 Original policy
81234DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) allelesColorado Prior Authorization List, Pg 97 Original policy
81235EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)Colorado Prior Authorization List, Pg 97 Original policy
81236EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequenceColorado Prior Authorization List, Pg 97 Original policy
81237EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)Colorado Prior Authorization List, Pg 97 Original policy
81239DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)Colorado Prior Authorization List, Pg 97 Original policy
81240F2 (Prothrombin, Coagulation Factor Ii) (Eg, Hereditary Hypercoagulability) Gene Analysis, 20210G>A VariantColorado Prior Authorization List, Pg 97 Original policy
81241F5 (Coagulation Factor V) (Eg, Hereditary Hypercoagulability) Gene Analysis, Leiden VariantColorado Prior Authorization List, Pg 98 Original policy
81242Fancc (Fanconi Anemia, Complementation Group C) (Eg, Fanconi Anemia, Type C) Gene Analysis, Common Variant (Eg, Ivs4+4A>T)Colorado Prior Authorization List, Pg 98 Original policy
81243FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis; evaluation to detect abnormal (eg, expanded) alColorado Prior Authorization List, Pg 98 Original policy
81244FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis; characterization of alleles (eg, expanded sizeColorado Prior Authorization List, Pg 98 Original policy
81245Flt3 (Fms-Related Tyrosine Kinase 3) (Eg, Acute Myeloid Leukemia), Gene Analysis, Internal Tandem Duplication (Itd) Variants (Ie, Exons 14, 15)Colorado Prior Authorization List, Pg 98 Original policy
81246FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836)Colorado Prior Authorization List, Pg 98 Original policy
81247G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, A, A-)Colorado Prior Authorization List, Pg 98 Original policy
81248G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)Colorado Prior Authorization List, Pg 98 Original policy
81249G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequenceColorado Prior Authorization List, Pg 98 Original policy
81250G6Pc (Glucose-6-Phosphatase, Catalytic Subunit) (Eg, Glycogen Storage Disease, Type 1A, Von Gierke Disease) Gene Analysis, Common Variants (Eg, R83C, Q347X)Colorado Prior Authorization List, Pg 98 Original policy
81251Gba (Glucosidase, Beta, Acid) (Eg, Gaucher Disease) Gene Analysis, Common Variants (Eg, N370S, 84Gg, L444P, Ivs2+1G>A)Colorado Prior Authorization List, Pg 98 Original policy
81252GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequenceColorado Prior Authorization List, Pg 98 Original policy
81253GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variantsColorado Prior Authorization List, Pg 98 Original policy
81254GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6-D13SColorado Prior Authorization List, Pg 98 Original policy
81255Hexa (Hexosaminidase A [Alpha Polypeptide]) (Eg, Tay-Sachs Disease) Gene Analysis, Common Variants (Eg, 1278Instatc, 1421+1G>C, G269S)Colorado Prior Authorization List, Pg 98 Original policy
81256Hfe (Hemochromatosis) (Eg, Hereditary Hemochromatosis) Gene Analysis, Common Variants (Eg, C282Y, H63D)Colorado Prior Authorization List, Pg 98 Original policy
81257HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; common deletions or variant (eg, SoutheastColorado Prior Authorization List, Pg 98 Original policy
81258HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variantColorado Prior Authorization List, Pg 98 Original policy
81259HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequenceColorado Prior Authorization List, Pg 99 Original policy
81260Ikbkap (Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells, Kinase Complex-Associated Protein) (Eg, Familial Dysautonomia) Gene Analysis, Common Variants (Eg, 2507+Colorado Prior Authorization List, Pg 99 Original policy
81261Igh@ (Immunoglobulin Heavy Chain Locus) (Eg, Leukemias And Lymphomas, B- Cell), Gene Rearrangement Analysis To Detect Abnormal Clonal Population(S); Amplified Methodology (EgColorado Prior Authorization List, Pg 99 Original policy
81262Igh@ (Immunoglobulin Heavy Chain Locus) (Eg, Leukemias And Lymphomas, B- Cell), Gene Rearrangement Analysis To Detect Abnormal Clonal Population(S); Direct Probe Methodology (EColorado Prior Authorization List, Pg 99 Original policy
81263Igh@ (Immunoglobulin Heavy Chain Locus) (Eg, Leukemia And Lymphoma, B- Cell), Variable Region Somatic Mutation AnalysisColorado Prior Authorization List, Pg 99 Original policy
81264Igk@ (Immunoglobulin Kappa Light Chain Locus) (Eg, Leukemia And Lymphoma, B-Cell), Gene Rearrangement Analysis, Evaluation To Detect Abnormal Clonal Population(S)Colorado Prior Authorization List, Pg 99 Original policy
81265Comparative Analysis Using Short Tandem Repeat (Str) Markers; Patient And Comparative Specimen (Eg, Pre-Transplant Recipient And Donor Germline Testing, Post-Transplant Non-HeColorado Prior Authorization List, Pg 99 Original policy
81266Comparative Analysis Using Short Tandem Repeat (Str) Markers; Each Additional Specimen (Eg, Additional Cord Blood Donor, Additional Fetal Samples From Different Cultures, Or AColorado Prior Authorization List, Pg 99 Original policy
81269HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variantsColorado Prior Authorization List, Pg 99 Original policy
81270Jak2 (Janus Kinase 2) (Eg, Myeloproliferative Disorder) Gene Analysis, P.Val617Phe (V617F) VariantColorado Prior Authorization List, Pg 99 Original policy
81271HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) allelesColorado Prior Authorization List, Pg 99 Original policy
81272KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequColorado Prior Authorization List, Pg 99 Original policy
81273KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene analysis, D816 variant(s)Colorado Prior Authorization List, Pg 99 Original policy
81274HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)Colorado Prior Authorization List, Pg 99 Original policy
81275Kras (V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene) (Eg, Carcinoma) Gene Analysis, Variants In Codons 12 And 13Colorado Prior Authorization List, Pg 99 Original policy
81276KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)Colorado Prior Authorization List, Pg 99 Original policy
81277Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalitiesColorado Prior Authorization List, Pg 99 Original policy
81278IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitativeColorado Prior Authorization List, Pg 99 Original policy
81279JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)Colorado Prior Authorization List, Pg 99 Original policy
81283IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variantColorado Prior Authorization List, Pg 99 Original policy
81284FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) allelesColorado Prior Authorization List, Pg 99 Original policy
81285FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)Colorado Prior Authorization List, Pg 99 Original policy
81286FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequenceColorado Prior Authorization List, Pg 99 Original policy
81287MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme) promoter methylation analysisColorado Prior Authorization List, Pg 99 Original policy
81288MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non- polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysisColorado Prior Authorization List, Pg 100 Original policy

Sources

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.